AI-generated summary
The authors report a double-blind randomized trial of 224 adolescent psychiatric inpatients with moderate or severe depression, comparing morning bright light therapy with placebo red light alongside usual inpatient care. Both groups showed a significant reduction in depression scores, but the authors found no added benefit of bright light therapy over placebo. Loss to follow-up was substantial, at 31 percent at 16 weeks and 49 percent at 28 weeks.
- Participants
- 224
- Who or what was studied
- Adolescent psychiatric inpatients aged 12 to 18 years with moderate to severe major depressive disorder at four university child and adolescent psychiatry hospitals in Germany
- Limits stated in the abstract
- Loss to follow-up was high, at 31 percent at 16 weeks and 49 percent at 28 weeks, and the abstract notes the study was limited to inpatients in Germany.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on jamanetwork.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Bright light therapy, Depression, Lux, Placebo-controlled, Trial registration, Red light therapy, Primary outcome. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.